The domestic market price and purchasing methods of vorasidenib-VORANIGO

Voranib (VORANIGO) is an oral small molecule IDH1/2 inhibitor, mainly used to treat patients with low-grade gliomas and related brain tumors carrying IDH1/2 mutations. The drug selectively inhibits the activity of IDH1/2 mutant enzyme and reduces the accumulation of 2-hydroxyglutarate (2-HG) in tumor cells, thereby inhibiting tumor growth and improving patient survival prognosis.

In the domestic market, Voxanib has not yet been launched, so it is not included in the medical insurance system and has no official retail price. Domestic patients are temporarily unable to purchase original drugs directly through hospitals or pharmacies, and can only rely on overseas channels or participation in clinical trials to obtain drug use opportunities. This limits the accessibility and convenience of medication to domestic patients.

In overseas markets, the US version of the original drug Voxanib is 40mg*30 tablets. Each box sells for about 380,000 yuan. The price may fluctuate due to exchange rates and purchase channels. This price is a high-end drug level for most patients, so the choice needs to be evaluated based on economic conditions and treatment needs.

It is worth noting that generic versions of Voxanib are already on the market in overseas markets. For example, the drug of the same specification produced by Lucius Pharmaceuticals in Laos is priced at more than 7,000 yuan per box, which is much lower than the original drug. The ingredients of this generic drug are basically the same as those of the original drug, which can provide patients with more economical treatment options. At the same time, they still need to follow the guidance of doctors when using them to ensure safety and efficacy.

Reference link:https://www.drugs.com